MaxCyte Inc.
10/01/2024 | Press release | Distributed by Public on 10/01/2024 00:47
Total Voting Rights
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
ROCKVILLE, MD, October 1, 2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications,announces thatpursuant to its block admission facility, since August 31, it has issued 128,480 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options and/or vesting of restricted stock units.
Total voting rights
As at September 30, 2024, the total issued stock capital of the Company following the recent issue of the new Common Stock is 105,298,880 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
For further information, please contact:
|
MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 |
|||
|
Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|||
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700 |
|||
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Byproviding our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.